Tulisokibart

Merck's tulisokibart (MK-7240) is an anti-TL1A monoclonal antibody whose Phase 3 ATLAS-UC induction-only study in moderately-to-severely active ulcerative colitis met its primary endpoint (clinical remission by Modified Mayo Score at Week 12) on June 22, 2026, making it the first anti-TL1A biologic to read out positive in Phase 3 [13]. A second Phase 3 UC program with induction plus maintenance (ATLAS-UC Study 1, NCT06052059) and the Phase 3 Crohn's program ARES-CD (NCT06430801, n=1,200, Week 52 clinical remission by Crohn's Disease Activity Index, or CDAI) are still ongoing [3][15]. Parallel Phase 2b programs run in axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis [4][5][6]. The drug arrived at Merck via the $10.8 billion Prometheus Biosciences acquisition (announced April 2023, closed June 2023) [8], and is one of three credible anti-TL1A programs alongside Sanofi/Teva's duvakitug and Roche's afimkibart (acquired via Telavant from Roivant/Pfizer in late 2023) [9][10]. Phase 2 readouts in NEJM (UC, 2024) and Lancet Gastroenterology & Hepatology (Crohn's induction, 2025) showed clean efficacy plus a 14-gene predictive biomarker derived from Prometheus's genetic database [1][2]. Analyst consensus peak sales sit at $4-5B with upside cases above $5B [14].

Tulisokibart is investigational and not approved anywhere, but the Phase 3 ATLAS-UC induction-only study hit its primary endpoint of clinical remission (Modified Mayo Score) at Week 12 on June 22, 2026 with a safety profile consistent with Phase 2; long-term maintenance and endoscopic data have not yet read out [13]. ATLAS-UC consists of two Phase 3 studies under NCT06052059: Study 1 (induction plus maintenance) and Study 2 (induction-only, the program that just hit) [15]. The Phase 3 Crohn's program ARES-CD (NCT06430801) is recruiting 1,200 patients with a Week 52 clinical remission primary endpoint defined by the Crohn's Disease Activity Index (CDAI) [3]. Phase 2 results are published: ulcerative colitis in NEJM 2024 (Sands et al.) [1] and Crohn's induction in Lancet Gastroenterology & Hepatology 2025 (Feagan et al.) [2]. Merck is also running Phase 2 studies in axial spondyloarthritis (NCT07133633, n=315) [4], psoriatic arthritis (NCT07486960, n=140) [5], and rheumatoid arthritis (NCT07176390, n=182) [6], plus an active Phase 1 healthy-participant pharmacokinetic study (NCT07405177) supporting line extensions [7]. No FDA breakthrough therapy or fast track designations have been publicly disclosed. With the ATLAS-UC induction win in hand, a first UC regulatory submission becomes plausible in 2027 once maintenance data are available, with Crohn's submission likely 2028 to 2029. Merck's fiscal year 2025 10-K (filed early 2026) referenced tulisokibart among Phase 3 immunology assets but did not commit to a specific milestone date [12].

TL1A is a signaling protein (a cytokine) on the surface of immune cells that tells T cells to ramp up and stay alive. In Crohn's and ulcerative colitis, T cells over-produce inflammatory signals that damage the gut lining. Tulisokibart binds TL1A and blocks it from reaching its main receptor (TNFRSF25), cooling the T cell response without broadly shutting down immunity the way TNF inhibitors can [1]. The mechanism is genetically credentialed: variants in TNFSF15 (the gene encoding TL1A) are associated with IBD risk, particularly in East Asian populations, and Open Targets ranks TL1A in the upper tier of IBD evidence at 0.52 for Crohn's and 0.49 for UC. TL1A also drives intestinal fibrosis, the slow tissue scarring that produces strictures in Crohn's and eventually forces bowel resection. If tulisokibart can dial down both inflammation and the fibrotic remodeling, it does something current biologics largely do not [2]. The catch: fibrosis endpoints have never been validated in IBD regulatory trials, so any anti-fibrotic benefit will register as durability of remission or steroid-free maintenance, not as a labeled anti-fibrotic claim.

ARES-CD (NCT06430801) enrolls 1,200 adults with moderate-to-severe Crohn's, randomized against placebo, with Week 52 clinical remission by CDAI as the primary endpoint [3]. Fifty-two weeks targets maintenance benefit rather than induction, the right bar in IBD where many drugs win at Week 12 then fade. Patients are stratified by prior advanced therapy exposure, allowing separate analysis in biologic-experienced versus biologic-naive (patients who have never received a biologic therapy) arms. That stratification matters commercially: most second-line IBD market value sits in TNF-failure patients, who are harder to move but worth more per script. ATLAS-UC (NCT06052059) is structured as two Phase 3 studies: Study 1 evaluates induction plus maintenance, Study 2 was induction-only and met its primary endpoint of clinical remission by Modified Mayo Score at Week 12 [13][15]. The Phase 2 UC trial used a 14-gene predictive biomarker built from the Prometheus genetic database to enrich for responders, and the biomarker-positive subgroup hit clinical remission at 32% (vs 11% placebo) versus the all-comers Cohort 1 result of 26% (vs 1% placebo) [1]. Whether Merck carried the biomarker into Phase 3 as an enrichment strategy or kept it as a pre-specified secondary analysis matters for label breadth and is not fully disclosed in public protocol materials.

Our model gives this drug a 66% chance of eventually being approved. That starts from the historical approval rate for Phase 3 drugs in this area, about 61%, then adjusts based on ten facts about the trial and sponsor. The estimate goes up because of strong earlier-phase results, a non-randomized design, and larger-than-typical enrollment; it comes down somewhat because of heavier-than-usual blinding. The remaining facts fall close to average for this stage, so they leave the final number near where the base rate started.

Efficacy risk has shifted. The Phase 3 UC induction win removes mechanism doubt for UC short-term remission [13], but the Crohn's Week 52 endpoint is a different bar - drugs that win at Week 12 often lose at Week 52 due to anti-drug antibody formation (where the immune system treats the drug as foreign and disables it) or loss of response. Without biomarker enrichment, biomarker-negative patients in the broad ARES-CD population could dilute the signal. A separate regulatory wrinkle: the FDA has been moving away from CDAI-only primary endpoints in Crohn's toward composite measures including patient-reported outcomes (abdominal pain, stool frequency) plus endoscopic assessment. If ARES-CD relies solely on CDAI without an endoscopic co-primary or key secondary, expect agency questions at filing - the protocol should be checked on this point. Safety risk is moderate. TL1A blockade is mechanistically cleaner than broad TNF suppression, but TL1A has roles in tumor surveillance and intracellular pathogen control. Long-term malignancy and serious infection signals will not be visible until pooled safety data accumulate across ATLAS-UC, ARES-CD, and the ~640 patients in the rheumatology programs. No black box signals have emerged so far [1][2][13]. Competitive risk is the dominant commercial threat. Sanofi/Teva's duvakitug posted positive Phase 2b maintenance data in February 2026 and entered Phase 3 in H2 2025, with readout expected around 2028 [9]. Roche's afimkibart (acquired via the Telavant deal with Roivant/Pfizer) is in Phase 3 with a subcutaneous dosing advantage versus tulisokibart's IV induction [10]. The first anti-TL1A to label captures the early specialist market; second to market in IBD biologics typically takes 20 to 30% of class share. Payer risk compounds this: another biologic in a market that already has TNF inhibitors, IL-23 inhibitors, JAK inhibitors, and S1P modulators (drugs that trap immune cells in lymph nodes, reducing gut inflammation) needs differentiated efficacy or a biomarker story to justify formulary placement against incoming biosimilars.

Worth watching closely. The Phase 3 ATLAS-UC induction win shifts tulisokibart from speculative to credible, but three follow-on data points convert it from credible to investable: ATLAS-UC maintenance data showing durable remission past Week 52; ARES-CD Phase 3 Crohn's data (especially in TNF-failure patients) showing tulisokibart matches or beats approved IL-23 inhibitors mirikizumab (Omvoh) and risankizumab (Skyrizi) - note ustekinumab (Stelara, IL-12/23) is also approved for both Crohn's and UC; and confirmation that the 14-gene biomarker strategy carried forward into Phase 3 in a way that enables a label-differentiating responder subgroup. Next check-in points: Merck's Q4 R&D day for updated timeline guidance and biomarker strategy disclosure, and the major GI meetings (Digestive Disease Week, ACG, United European Gastroenterology Week) where ATLAS-UC detailed data should present. Watch Sanofi/Teva's duvakitug Phase 3 readout (expected ~2028) and Roche's afimkibart Phase 3 progress. If duvakitug or afimkibart Phase 3 reads out positive within 12 months of tulisokibart's UC filing, the commercial case narrows materially. The commercial context: Merck paid $10.8 billion for Prometheus, with tulisokibart as the headline asset [8]. Analyst peak sales consensus sits at $4-5B with Guggenheim modeling above $5B by the late 2030s [14] - a reasonable return profile against the acquisition price assuming approval. Keytruda loses U.S. exclusivity in 2028, and Merck has been buying its way into post-Keytruda franchises (Verona, Prometheus, Acceleron earlier). The IBD biologics market is $25 billion plus and growing. The bet is rational, the science is real, and the execution risk is now mostly about beating Roche and Sanofi to label across UC and Crohn's, plus proving the biomarker translates. Patent runway extends into the late 2030s for the composition-of-matter claims, giving roughly a decade of branded sales before biosimilar entry - long enough to recoup the acquisition cost if peak sales hit the lower bound. NOT investment advice.

This writeup is for research/intelligence purposes and is not investment advice.